The median EPS estimate is $0.95 calculated after taking 2 analyst projections. Now the company has earned “Buy” from 1 equity analysts. Addressing reporters at a conference call on Thursday afternoon, Wynn bemoaned the low profitability of table games at casinos throughout the U.S. The company is considering incremental improvements to increase the odds for the house at various table games, Wynn added.
Advertisement
Major casino operator Wynn Resorts Ltd. published on Thursday its financial results for the three months ended June 30, 2016 and provided updates on its Wynn Palace integrated casino resort, slated to open doors on Macau’s Cotai Strip on August 22. (NYSE:V) said that, two payment companies just announced a wide-ranging partnership that includes a promise from PayPal to stop steering Visacard holders away from using their Visa cards for PayPal transactions. The value of bullish trades on upticks was $4.08 million, whereas, investors only sold shares worth $2.81 million on downticks. Eleven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Analyst’s mean target price for Eleven Biotherapeutics, Inc. Brokerages covering the stock are now expecting the firm to earn $0.95 per share based on the 11 covering brokerages weighted into that average.
Netflix, Inc. (NASDAQ:NFLX) is a platform for addictive TV series which allows subscribers to binge-watch and complete a season in a weekend. The firm exchanged hands at a volume of 2849424. A total of 258,523 shares were purchased at an average price of $58.48. In the past 52 weeks, the equity’s price traded between $11.35 and $ 50.08. After the day began at $16.24, the company was seen hitting $16.59 as its intraday high price and $16.02 as its bottom price.
Now the return on equity is -216.70% and its debt to equity is *TBA. The simple moving average for the last 200 days stands at 28.29%. Its RSI (Relative Strength Index) reached 54.34.
Advertisement
On a consensus basis, Wall Street sell-side analysts have a mean target price of $23.75 for Merit Medical Systems, Inc. Previously, the analysts had a Buy rating on the shares. The rating firm gave a Neutral rating to this stock in a research note on Jul 14, 2016. 18 analysts have suggested the company is a “Hold”. The company has an Average Rating of 2.34 based on Thomson Reuters I/B/E/S scale of 1-5.
